NanoViricides Opens New Facility in Shelton, CT for Production of Drug Candidates

NanoViricides, Inc. (NYSE MKT:NNVC) opened its new R&D and cGMP pilot manufacturing facility with U.S. Congressman Jim Himes performing the ribbon cutting to inaugurate the facility on July 21, 2014.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The company’s novel nanoviricide® class of drug candidates is designed to specifically attack enveloped virus particles and dismantle them.

Read more »

The First OneMedMarket Conference

On May 21, 2014, the first OneMedMarket conference was held in New York City. Accredited investors turned out from all […]

Read more »

Editor’s Note

Dear Subscriber, In the coming weeks, the sentinel will be featuring articles on emerging private growth companies in the health […]

Read more »

The Whirl of Wound Care

However irksome it may be to think about open or healing wounds, the medical advances and market potential in this niche space is quite appealing for investors. Globally, there are 50 million reported cases of patients suffering from some type of wound that may be difficult to close or heal.

Read more »

SpectraScience: Innovations in Cancer Detection

SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.

Read more »

DesignMedix: Overcoming Drug Resistance

DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer.

Read more »

BioLife Solutions: Powering the Preservation Sciences

BioLife Solutions has a strong interest in target markets: regenerative medicine, biobanking, and drug discovery.

Read more »

Avantis Medical Systems Enters Enormous Endoscope Market

Avantis Medical Systems is company that is tapping into large Endoscope market which has 30 million colonoscopies globally and 15 million in the US alone.

Read more »

International Stem Cell Corporation Progressing in Human Induced Stem Cells

International Stem Cell Corporation (OTCQB: ISCO) is a biotechnology company that focuses on developing novel stem cell based therapies. Most recently, they have made significant progress in human induced pluripotent stem cells (iPS) and its derivation with novel protein-based reprogramming method.

Read more »

Plandai Biotechnology Sets for Battle Against Neurological Diseases by using Nutraceuticals

Plandaí­ Biotechnology, Inc. (OTCQB: PLPL) transforming the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. These extracts are utilized to deliver a new family of drugs to safely and cost effectively treats a plethora of different diseases and conditions.

Read more »